Vedolizumab (Entyvio)

Gut-selective integrin blocker (anti-integrin)

Indications

UC and CD in adults, mainly when infliximab or adalimumab have not been effective or there is a reason the patient cannot take these

Contraindications

Severe active infection. Caution in history of recurring infection. Patients should be screened for tuberculosis and up to date with immunisation before starting treatment. Use in pregnancy if benefit outweighs risk and with caution while breastfeeding. | Potential side effects: Joint pain; constipation; cough; fatigue; fever; gastrointestinal discomfort and disorders; headache; high blood pressure; increased risk of infection; muscle spasms and weakness; nasal congestion; nausea; night sweats; neck and throat pain; skin reactions

Preparations Available

Intravenous infusion; subcutaneous injection

Quantity

Dose: 300mg infusion initally, after 2 weeks, 4 weeks and every 8 weeks; 108mg injection (for maintance) every 2 weeks after at least 2 intravenous infusions

Sizes Available

108mg/0.68ml solution for pre-filled pens (1), £512.50; 108mg/0.68ml solution for pre-filled pens (2), £1025.00; 108mg/0.68ml solution for pre-filled syringes (2), £1025.00; 300mg powder for infusion vials, £2050.00